Asia-Pacific region macular degeneration market to see modest growth; report

30 October 2013

Due to the absence of promising products in the pipeline or expected new drug launches, the macular degeneration market in the Asia-Pacific region (India, Australia, China and Japan) is expected to experience moderate growth, says business intelligence provider GBI Research.

The therapy sector is expected to increase from $675.7 million in 2012 to $1,016.1 million by 2019, expanding at a compound annual growth rate (CAGR) of 6%. According to GBI’s latest report, Japan represented 53% of the macular degeneration market in the Asia-Pacific region in 2012, followed by Australia, with a 33% share. Although there are currently no prominent drug launches scheduled, the market is set to grow moderately due to an increase in the region’s aging population.

Additionally, in 2012, around 98% of the global wet age-related macular degeneration (AMD) market revenue was generated by anti-angiogenic therapies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK